137 related articles for article (PubMed ID: 10407985)
41. Effects of a formulary change from granulocyte colony-stimulating factor to granulocyte-macrophage colony-stimulating factor on outcomes in patients treated with myelosuppressive chemotherapy.
Wong SF; Chan HO
Pharmacotherapy; 2005 Mar; 25(3):372-8. PubMed ID: 15843284
[TBL] [Abstract][Full Text] [Related]
42. Recombinant human GM-CSF in small cell lung cancer: a phase I/II study.
Anderson H; Gurney H; Thatcher N; Swindell R; Scarffe JH; Weiner J
Recent Results Cancer Res; 1991; 121():155-61. PubMed ID: 1650015
[TBL] [Abstract][Full Text] [Related]
43. Randomized placebo-controlled trial of granulocyte-macrophage colony-stimulating-factor support for dose-intensive cyclophosphamide, etoposide, and cisplatin.
Yau JC; Neidhart JA; Triozzi P; Verma S; Nemunaitis J; Quick DP; Mayernik DG; Oette DH; Haynes FA; Holcenberg J
Am J Hematol; 1996 Apr; 51(4):289-95. PubMed ID: 8602629
[TBL] [Abstract][Full Text] [Related]
44. Completion and toxicity of induction chemotherapy for metastatic testicular cancer: an updated evaluation of Japanese patients.
Kawai K; Ando S; Hinotsu S; Oikawa T; Sekido N; Miyanaga N; Shimazui T; Akaza H
Jpn J Clin Oncol; 2006 Jul; 36(7):425-31. PubMed ID: 16790450
[TBL] [Abstract][Full Text] [Related]
45. Mobilization of peripheral blood stem cells following myelosuppressive chemotherapy: a randomized comparison of filgrastim, sargramostim, or sequential sargramostim and filgrastim.
Weaver CH; Schulman KA; Buckner CD
Bone Marrow Transplant; 2001 May; 27 Suppl 2():S23-9. PubMed ID: 11436117
[TBL] [Abstract][Full Text] [Related]
46. Effect of rhGM-CSF on haematopoietic reconstitution after chemotherapy in small-cell lung cancer.
Havemann K; Klausmann M; Wolf M; Fischer JR; Drings P; Oster W
J Cancer Res Clin Oncol; 1991; 117 Suppl 4():S203-7. PubMed ID: 1665493
[TBL] [Abstract][Full Text] [Related]
47. The use of granulocyte colony-stimulating factor to shorten the interval between cycles of mitomycin C, vindesine, and cisplatin chemotherapy in non-small-cell lung cancer.
Takada M; Fukuoka M; Ariyoshi Y; Furuse K; Niitani H; Ota K; Motomiya M; Hasegawa K; Tominaga K; Kuriyama T
Cancer Chemother Pharmacol; 1992; 31(3):182-6. PubMed ID: 1281446
[TBL] [Abstract][Full Text] [Related]
48. Granulocyte-colony-stimulating factor enhances the circulating hematopoietic progenitors in lung cancer patients treated with cisplatin-containing regimens.
Mukai J; Shimizu E; Ogura T
Jpn J Cancer Res; 1992 Jul; 83(7):746-53. PubMed ID: 1381342
[TBL] [Abstract][Full Text] [Related]
49. [Effectiveness of sequential administration of G-CSF and GM-CSF after antineoplastic chemotherapy in patients with advanced tumors: results of a randomized trial].
Mustacchi G; Ceccherini R; Milani S; Sandri P; Leita ML; Carbonara T
Tumori; 1997; 83(5 Suppl):S13-6. PubMed ID: 9446253
[TBL] [Abstract][Full Text] [Related]
50. [Successful collection of peripheral blood stem cells mobilized by high-dose etoposide for patients with chemotherapy-resistant and/or poor prognostic testicular cancer].
Nakagawa S; Sugimoto K; Mikami K; Watanabe H; Sonoda Y; Kuzuyama Y; Abe T; Fujii H
Nihon Hinyokika Gakkai Zasshi; 1994 Apr; 85(4):571-8. PubMed ID: 7514697
[TBL] [Abstract][Full Text] [Related]
51. Hematopoietic recovery following high-dose combined alkylating-agent chemotherapy and autologous bone marrow support in patients in phase-I clinical trials of colony-stimulating factors: G-CSF, GM-CSF, IL-1, IL-2, M-CSF.
Laughlin MJ; Kirkpatrick G; Sabiston N; Peters W; Kurtzberg J
Ann Hematol; 1993 Dec; 67(6):267-76. PubMed ID: 7506580
[TBL] [Abstract][Full Text] [Related]
52. The role of granulocyte-macrophage colony-stimulating factor in the treatment of germ cell tumors. German Testicular Cancer Study Group.
Bokemeyer C; Harstrick A; Rüther U; Metzner B; Illiger HJ; Clemm C; Siegert W; Link H; Ostermann H; Schmoll HJ
Semin Oncol; 1994 Dec; 21(6 Suppl 16):57-63. PubMed ID: 7801148
[TBL] [Abstract][Full Text] [Related]
53. Granulocyte-macrophage colony-stimulating factor (GM-CSF) priming of high-dose etoposide and cyclophosphamide: a pilot trial.
Bernstein SH; Christiansen NP; Fay JP; Brown R; Herzig R; Frankel S; Blumenson L; Herzig GP
Exp Hematol; 1996 Oct; 24(12):1363-8. PubMed ID: 8913281
[TBL] [Abstract][Full Text] [Related]
54. Recombinant human granulocyte and granulocyte-macrophage colony-stimulating factor (G-CSF and GM-CSF) administered following cytotoxic chemotherapy have a similar ability to mobilize peripheral blood stem cells.
Hohaus S; Martin H; Wassmann B; Egerer G; Haus U; Färber L; Burger KJ; Goldschmidt H; Hoelzer D; Haas R
Bone Marrow Transplant; 1998 Oct; 22(7):625-30. PubMed ID: 9818688
[TBL] [Abstract][Full Text] [Related]
55. FEP regimen (epidoxorubicin, etoposide and cisplatin) in advanced gastric cancer, with or without low-dose GM-CSF: an Italian Trial in Medical Oncology (ITMO) study.
Bajetta E; Di Bartolomeo M; Carnaghi C; Buzzoni R; Mariani L; Gebbia V; Comella G; Pinotti G; Ianniello G; Schieppati G; Bochicchio AM; Maiorino L
Br J Cancer; 1998 Apr; 77(7):1149-54. PubMed ID: 9569054
[TBL] [Abstract][Full Text] [Related]
56. Abrogating chemotherapy-induced myelosuppression by recombinant granulocyte-macrophage colony-stimulating factor in patients with sarcoma: protection at the progenitor cell level.
Vadhan-Raj S; Broxmeyer HE; Hittelman WN; Papadopoulos NE; Chawla SP; Fenoglio C; Cooper S; Buescher ES; Frenck RW; Holian A
J Clin Oncol; 1992 Aug; 10(8):1266-77. PubMed ID: 1634916
[TBL] [Abstract][Full Text] [Related]
57. [The hematopoietic growth factor GM-CSF in chemotherapy for ovarian carcinoma].
Biesma B; Willemse PH; Vellenga E; Limburg PC; Aalders JG; de Vries EG
Ned Tijdschr Geneeskd; 1991 Mar; 135(10):420-4. PubMed ID: 2020314
[TBL] [Abstract][Full Text] [Related]
58. Accelerated chemotherapy with or without GM-CSF for small cell lung cancer: a non-randomised pilot study.
Ardizzoni A; Sertoli MR; Corcione A; Pennucci MC; Baldini E; Intra E; Ferrarini M; Rosso R; Mazzanti P; Pistoia V
Eur J Cancer; 1990; 26(9):937-41. PubMed ID: 2177614
[TBL] [Abstract][Full Text] [Related]
59. Repetitive cycles of cyclophosphamide, thiotepa, and carboplatin intensification with peripheral-blood progenitor cells and filgrastim in advanced breast cancer patients.
Shapiro CL; Ayash L; Webb IJ; Gelman R; Keating J; Williams L; Demetri G; Clark P; Elias A; Duggan D; Hayes D; Hurd D; Henderson IC
J Clin Oncol; 1997 Feb; 15(2):674-83. PubMed ID: 9053493
[TBL] [Abstract][Full Text] [Related]
60. A study of filgrastim (rG-CSF) priming of etoposide/cisplatin in advanced non-small cell lung cancer.
Mehdi SA; Perry MC; Herndon JE; Crawford J; Young R; Graziano SL
J Interferon Cytokine Res; 1998 Aug; 18(8):623-7. PubMed ID: 9726444
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]